Dermatological Therapeutic Pipeline

Manuka Bioscience is developing a pipeline of botanical dermatological drug candidates for global markets. These therapeutics are based on East Cape mānuka oil and other synergistic actives. These include ECMT-154 with broad-based antimicrobial and anti-inflammatory applications, ECMT-304 for moderate to severe adult acne and ECMT-220 for fungal infections. We are now creating innovative products for important market segments with unmet needs.

Botanical Dermatological Drug Pipeline





Impetigo (school sores) and other bacterial skin and would infections

Impetigo clinical trial underway


Eczema and other imflammatory skin conditions

Eczema clinical trial recruitment as of September 2021


Moderate to severe adult acne

Consumer trial in 2021


Fungal infections such as athletes foot and ringworm

Under development


Herpes infections

R&D in progress

ECMT-154 Antibacterial

Independent scientific studies show that East Cape Mānuka Oil based ECMT-154 has demonstrated efficacy against bacteria that cause bacterial skin and wound infections such as Staphylococcus aureus, Streptococcus pyogenes and Methicillin Resistant Staphylococcus aureus or MRSA (superbug). These pathogens cause common, contagious and painful bacterial infections such as impetigo (school sores), sties, abscesses, boils, folliculitis, cellulitis, carbuncles and furuncles. These bacteria also cause serious and often life threatening surgical and non-surgical wound infections, and necrotizing fasciitis (flesh eating bacterial disease).

ECMT-154 Anti-inflammatory

Eczema, also known as atopic dermatitis, is a common chronic inflammatory skin disease characterized by recurrent flares of dry red and itchy skin lesions and subsequent remissions. The condition has a considerable impact on quality of life because of skin discomfort and sleep disturbances. Independent scientific studies show that ECMT-154 is suitable in the treatment of eczema.

ECMT-304 Anti-acne

Acne is a chronic inflammatory skin condition that is associated with the bacteria Cutibacterium acnes and Staphylococcus epidermidis. It is a very common condition that affects 85% of teenagers and 14% of adults. Acne begins when hair follicles become plugged with oil and dead skin cells. It often causes whiteheads, blackheads or pimples, and usually appears on the face, forehead, chest, upper back and shoulders. ECMT-304 combines the anti-acne power of East Cape Mānuka Oil based ECMT-154 with selected synergistic actives to fight bacteria, reduce inflammation and scarring, and calm the skin.

ECMT-220 Anti-fungal

Independent testing shows that East Cape Mānuka Oil based ECMT-220 has strong efficacy against fungi such as Trichophyton mentagrophytes and Trichophyton rubrum that cause infections such as athletes foot, ring worm and jock itch. Manuka Bioscience is developing a new antifungal product to treat these conditions.

ECMT-XYZ Anti-viral

East Cape mānuka oil is renowned for its outstanding antiviral properties, particularly in the treatment of herpes simplex viruses (HSV) that cause cold sores and genital herpes. Manuka Bioscience is developing proprietary formulations to treat cold sores, as well as the painful skin condition shingles (herpes zoster) that is caused by the varicella zoster virus that also causes chickenpox.